Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
Clin Gastroenterol Hepatol. 2019 Feb;17(3):543-550.e2. doi: 10.1016/j.cgh.2018.07.006. Epub 2018 Sep 11.
BACKGROUND & AIMS: The effects of weight change on the progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) in the general population are unclear. We evaluated the association of weight change and baseline body mass index (BMI) with fibrosis progression, determined by non-invasive measurement of a marker, in young and middle-aged adults with NAFLD.
We performed a prospective cohort study of 40,700 adults with NAFLD in Korea who received regular health screening examinations and were followed for a median 6.0 years. Weight change was defined as the difference between weights measured at baseline and at a subsequent follow-up visit. The progression from a low to an intermediate or high probability of advanced fibrosis was assessed using the aspartate aminotransferase to platelet ratio index (APRI).
During 275,421.5 person-years of follow-up, 5454 subjects with a low APRI progressed to an intermediate or high APRI. Multivariable-adjusted hazard ratios for APRI progression, determined by comparing the first and second weight change quintiles (the weight-loss group) and the fourth and fifth quintiles (weight-gain group) with the third quintile (weight-stable group, reference), were 0.68 (95% CI, 0.62-0.74), 0.86 (95% CI, 0.78-0.94), 1.17 (95% CI, 1.07-1.28), and 1.71 (95% CI, 1.58-1.85), respectively. The multivariable-adjusted hazard ratios for APRI progression were determined by comparing subjects with BMIs of 23-24.9, 25-29.9, and ≥30 with subjects with BMIs of 18.5-22.9 kg/m (reference); these ratios were 1.13 (95% CI, 1.02-1.26), 1.41 (95% CI, 1.28-1.55), and 2.09 (95% CI, 1.86-2.36), respectively.
In a prospective cohort study of 40,700 adults with NAFLD, we found obesity and weight gain to be independently associated with increased risk of fibrosis progression, based on APRI. Maintaining a normal healthy weight and preventing weight gain may help reduce fibrosis progression in individuals with NAFLD.
非酒精性脂肪性肝病(NAFLD)患者体重变化对肝纤维化进展的影响在普通人群中尚不清楚。我们评估了体重变化和基线体重指数(BMI)与非侵入性检测标志物测定的纤维化进展的相关性,该研究纳入了韩国的年轻和中年 NAFLD 患者。
我们对韩国 40700 例接受常规健康筛查并随访中位数为 6.0 年的 NAFLD 患者进行了前瞻性队列研究。体重变化定义为基线和后续随访时体重的差异。采用天门冬氨酸氨基转移酶与血小板比值指数(APRI)评估从低概率进展为中或高概率的晚期纤维化。
在 275421.5 人年的随访期间,5454 例 APRI 较低的患者进展为中或高 APRI。通过比较第一和第二体重变化五分位数(减重组)与第四和第五五分位数(增重组)与第三五分位数(体重稳定组,参考组),多变量调整的 APRI 进展风险比分别为 0.68(95%CI,0.62-0.74)、0.86(95%CI,0.78-0.94)、1.17(95%CI,1.07-1.28)和 1.71(95%CI,1.58-1.85)。通过比较 BMI 为 23-24.9、25-29.9 和≥30 的患者与 BMI 为 18.5-22.9 kg/m²(参考)的患者,多变量调整的 APRI 进展风险比分别为 1.13(95%CI,1.02-1.26)、1.41(95%CI,1.28-1.55)和 2.09(95%CI,1.86-2.36)。
在一项对 40700 例 NAFLD 成年患者的前瞻性队列研究中,我们发现肥胖和体重增加与 APRI 测定的纤维化进展风险增加独立相关。保持健康的正常体重和预防体重增加可能有助于减少 NAFLD 患者的纤维化进展。